Biogen (BIIB) Receives a Buy from Cowen & Co.

Cowen & Co. analyst Phil Nadeau maintained a Buy rating on Biogen (BIIBResearch Report) today and set a price target of $325.00. The company’s shares closed last Monday at $291.15.

According to, Nadeau is a 4-star analyst with an average return of 6.7% and a 50.1% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Phasebio Pharmaceuticals, Alexion Pharmaceuticals, and BioMarin Pharmaceutical.

The word on The Street in general, suggests a Hold analyst consensus rating for Biogen with a $306.96 average price target.

See today’s analyst top recommended stocks >>

Biogen’s market cap is currently $52.76B and has a P/E ratio of 10.40. The company has a Price to Book ratio of 3.80.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.